Parkview Hospital
- Type
- Teaching hospital
- Where
- Fort Wayne, IN
- Medicare CCN
- 150021
- Received
- $2,007,400 in 168 records, 2021 ($41,723 general, $1,965,676 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: PARKVIEW HOSPITAL INC Fuzzy (name and state)
- Federal award recipient: PARKVIEW HOSPITAL, INC. Fuzzy (name and state)
- Nonprofit: PARKVIEW HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 51 | $41,723 |
| 2021 | Research payment | 117 | $1,965,676 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 21 | $1,602,470 | 2021 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $90,451 | 2021 |
| Incyte Corporation | 26 | $70,100 | 2021 |
| Eli Lilly and Company | 3 | $34,619 | 2021 |
| AstraZeneca UK Limited | 1 | $33,369 | 2021 |
| Tandem Diabetes Care, Inc. | 32 | $28,050 | 2021 |
| Genentech, Inc. | 11 | $23,309 | 2021 |
| Boston Scientific Corporation | 13 | $23,038 | 2021 |
| Janssen Research & Development, LLC | 6 | $21,008 | 2021 |
| Novocure GmbH | 4 | $19,249 | 2021 |
| American Regent | 3 | $11,907 | 2021 |
| Erbe Elektromedizin GmbH | 1 | $9,500 | 2021 |
| Digital Diagnostics Inc. | 9 | $7,500 | 2021 |
| Stryker Corporation | 2 | $7,215 | 2021 |
| AstraZeneca Pharmaceuticals LP | 3 | $6,500 | 2021 |
| Shockwave Medical, Inc | 1 | $5,000 | 2021 |
| Linde Gas & Equipment Inc. | 12 | $4,627 | 2021 |
| Abbott Laboratories | 6 | $3,909 | 2021 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $1,500 | 2021 |
| Endologix LLC | 2 | $1,240 | 2021 |
| NuVasive, Inc. | 2 | $1,041 | 2021 |
| BIOTRONIK INC. | 4 | $747 | 2021 |
| MOLNLYCKE HEALTH CARE US, LLC | 1 | $500 | 2021 |
| UROGEN PHARMA, INC. | 1 | $351 | 2021 |
| Cochlear Americas | 1 | $194 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 117 | $1,965,676 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 32 | $28,050 |
| Space rental or facility fees (teaching hospital only) | 16 | $8,127 |
| Long term medical supply or device loan | 2 | $5,194 |
| Gift | 1 | $351 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $215,023 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $201,982 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $157,397 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $78,167 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $50,526 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,844 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $27,112 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $20,996 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $14,914 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,093 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,000 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2021 |
| 2021-12-31 | Shockwave Medical, Inc | $5,000 | Long term medical supply or device loan | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Lithoplasty | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,489 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2021 |
| 2021-12-29 | Merck Sharp & Dohme LLC | $90,124 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2021 |
| 2021-12-29 | Tandem Diabetes Care, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-23 | Merck Sharp & Dohme LLC | $217,169 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy vers | 2021 |
| 2021-12-21 | Takeda Pharmaceuticals U.S.A., Inc. | $46,719 | Research payment | Cash or cash equivalent | TRINTELLIX Drug, NEUROSCIENCE | Understanding Treatment of Major Depressive Disorder Patterns among Patients Treated with Trintellix in a Real-World Set | 2021 |
| 2021-12-21 | Incyte Corporation | $8,967 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-12-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-12-20 | Boston Scientific Corporation | $5,146 | Research payment | Cash or cash equivalent | Axios Device, Stents | A MULTICENTER PROSPECTIVE STUDY OF EUS GUIDED TRANSLUMINAL | 2021 |
| 2021-12-15 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-08 | Tandem Diabetes Care, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-03 | Merck Sharp & Dohme LLC | $44,609 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2021 |
| 2021-12-01 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-11-23 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-11-19 | Genentech, Inc. | $3,364 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-11-18 | Incyte Corporation | $1,706 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2021 | |
| 2021-11-17 | Novocure GmbH | $5,215 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2021 |
| 2021-11-17 | Tandem Diabetes Care, Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-11-12 | Merck Sharp & Dohme LLC | $207,542 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-11-10 | Abbott Laboratories | $1,212 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-11-10 | Novocure GmbH | $859 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2021 |
| 2021-11-08 | Novocure GmbH | $1,675 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2021 |
| 2021-11-05 | MOLNLYCKE HEALTH CARE US, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mepilex Border Sacrum Device, Wound Care | 2021 | |
| 2021-11-04 | Genentech, Inc. | $1,682 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-11-04 | NuVasive, Inc. | $741 | Research payment | Cash or cash equivalent | Simplify Cervical Artificial Disc Device, Cervicothoracic | Two Level Simplify Cervical Artificial Disc IDE Study | 2021 |
| 2021-11-04 | NuVasive, Inc. | $300 | Research payment | Cash or cash equivalent | Simplify Cervical Artificial Disc Device, Cervicothoracic | Two Level Simplify Cervical Artificial Disc IDE Study | 2021 |
| 2021-11-03 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-10-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-10-20 | American Regent | $5,052 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2021 |
| 2021-10-19 | Janssen Research & Development, LLC | $1,692 | Research payment | Cash or cash equivalent | A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure | 2021 | |
| 2021-10-13 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-10-08 | Merck Sharp & Dohme LLC | $5,938 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2021 |
| 2021-09-23 | Stryker Corporation | $3,000 | Research payment | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | EVALUATION FO THE SAGE AIRTAP LIFT COMPATIBLE (LC) DEVICE IN ICU | 2021 |
| 2021-09-22 | Tandem Diabetes Care, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-09-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-09-20 | Merck Sharp & Dohme LLC | $5,036 | Research payment | Cash or cash equivalent | Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2021 |
| 2021-09-20 | Boston Scientific Corporation | $4,845 | Research payment | Cash or cash equivalent | Axios Device, Stents | A MULTICENTER PROSPECTIVE STUDY OF EUS GUIDED TRANSLUMINAL | 2021 |
| 2021-09-20 | Genentech, Inc. | $1,200 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IMVIGOR 130 | 2021 |
| 2021-09-20 | Boston Scientific Corporation | $220 | Research payment | Cash or cash equivalent | Axios Device, Stents | A MULTICENTER PROSPECTIVE STUDY OF EUS GUIDED TRANSLUMINAL | 2021 |
| 2021-09-16 | Novocure GmbH | $11,500 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2021 |
| 2021-09-16 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-09-16 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-09-16 | Incyte Corporation | $225 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-09-14 | Janssen Research & Development, LLC | $960 | Research payment | Cash or cash equivalent | A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure | 2021 | |
| 2021-09-08 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-09-01 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-08-31 | Digital Diagnostics Inc. | $1,260 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-08-25 | Tandem Diabetes Care, Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-08-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-08-20 | Endologix LLC | $744 | Research payment | Cash or cash equivalent | AFX2 Bifurcated Endograft System Device, Cardiology/Vascular Diseases | LEOPARD | 2021 |
| 2021-08-18 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-08-18 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-08-13 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-08-13 | Incyte Corporation | $675 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-08-13 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-08-13 | Incyte Corporation | $225 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-08-04 | Merck Sharp & Dohme LLC | $18,500 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2021 |
| 2021-08-04 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-08-04 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-07-31 | Digital Diagnostics Inc. | $150 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-07-28 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-07-27 | Incyte Corporation | $1,705 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-07-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-07-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-07-20 | Janssen Research & Development, LLC | $3,873 | Research payment | Cash or cash equivalent | A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure | 2021 | |
| 2021-07-19 | Boston Scientific Corporation | $1,750 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US | 2021 |
| 2021-07-14 | American Regent | $3,500 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2021 |
| 2021-07-12 | Eli Lilly and Company | $8,250 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 IN | 2021 | |
| 2021-07-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-07-07 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-06-30 | Tandem Diabetes Care, Inc. | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-06-30 | Digital Diagnostics Inc. | $420 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-06-24 | Incyte Corporation | $17,500 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled i | 2021 | |
| 2021-06-23 | Tandem Diabetes Care, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-06-22 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-06-21 | Boston Scientific Corporation | $3,179 | Research payment | Cash or cash equivalent | Axios Device, Stents | A MULTICENTER PROSPECTIVE STUDY OF EUS GUIDED TRANSLUMINAL | 2021 |
| 2021-06-21 | Boston Scientific Corporation | $1,634 | Research payment | Cash or cash equivalent | Axios Device, Stents | A MULTICENTER PROSPECTIVE STUDY OF EUS GUIDED TRANSLUMINAL | 2021 |
| 2021-06-21 | Boston Scientific Corporation | $695 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US | 2021 |
| 2021-06-17 | Takeda Pharmaceuticals U.S.A., Inc. | $43,732 | Research payment | Cash or cash equivalent | TRINTELLIX Drug, NEUROSCIENCE | Understanding Treatment of Major Depressive Disorder Patterns among Patients Treated with Trintellix in a Real-World Set | 2021 |
| 2021-06-16 | Tandem Diabetes Care, Inc. | $1,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-06-09 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-06-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-05-31 | Digital Diagnostics Inc. | $1,380 | Research payment | Cash or cash equivalent | IDX-DR Device, Ophthalmology | IDx-DR | 2021 |
| 2021-05-26 | Abbott Laboratories | $556 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-05-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-05-19 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-05-17 | Boston Scientific Corporation | $132 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US | 2021 |
| 2021-05-14 | Merck Sharp & Dohme LLC | $94,543 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Trial of Pembrolizumab MK-3475 in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Partici | 2021 |
| 2021-05-13 | Erbe Elektromedizin GmbH | $9,500 | Research payment | Cash or cash equivalent | Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique (BURN | 2021 | |
| 2021-05-12 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-05-10 | Incyte Corporation | $2,339 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-05-07 | Incyte Corporation | $1,750 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2021 | |
| 2021-05-07 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2021 | |
| 2021-05-07 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2021 | |
| 2021-05-05 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-04-30 | Digital Diagnostics Inc. | $2,430 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-04-23 | Genentech, Inc. | $967 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-04-20 | Janssen Research & Development, LLC | $6,632 | Research payment | Cash or cash equivalent | A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure | 2021 | |
| 2021-04-19 | Eli Lilly and Company | $20,619 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 IN | 2021 | |
| 2021-04-16 | Incyte Corporation | $450 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-04-14 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-04-12 | Incyte Corporation | $113 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-04-08 | Abbott Laboratories | $186 | Research payment | Cash or cash equivalent | Optisure Defibrillation ICD Lead Device, Cardiac Rhythm Management | Optisure Lead Post Approval Study | 2021 |
| 2021-04-08 | Abbott Laboratories | $93 | Research payment | Cash or cash equivalent | Optisure Defibrillation ICD Lead Device, Cardiac Rhythm Management | Optisure Lead Post Approval Study | 2021 |
| 2021-04-06 | Linde Gas & Equipment Inc. | $594 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REGULATOR NOXBOXI SPECIFY CONN Device, Respiratory | 2021 | |
| 2021-04-01 | Stryker Corporation | $4,215 | Research payment | Cash or cash equivalent | SAGE AIR TAP LC Device, MEDICAL | EVALUATION FO THE SAGE AIRTAP LIFT COMPATIBLE (LC) DEVICE IN ICU | 2021 |
| 2021-03-31 | AstraZeneca Pharmaceuticals LP | $5,000 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2021 |
| 2021-03-31 | Digital Diagnostics Inc. | $1,560 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-03-31 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-03-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-03-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | NOxBOX-I Device, Respiratory | 2021 | |
| 2021-03-30 | Genentech, Inc. | $1,682 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-03-26 | Genentech, Inc. | $3,700 | Research payment | Cash or cash equivalent | Drug | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2021 |
| 2021-03-26 | Incyte Corporation | $2,712 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-03-24 | UROGEN PHARMA, INC. | $351 | Gift | In-kind items and services | JELMYTO Drug, UROTHELIAL CANCER | 2021 | |
| 2021-03-24 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-03-15 | Boston Scientific Corporation | $1,591 | Research payment | Cash or cash equivalent | Axios Device, Stents | A MULTICENTER PROSPECTIVE STUDY OF EUS GUIDED TRANSLUMINAL | 2021 |
| 2021-03-10 | Tandem Diabetes Care, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-03-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2021 |
| 2021-03-09 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2021 |
| 2021-03-09 | BIOTRONIK INC. | $166 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2021 |
| 2021-03-09 | BIOTRONIK INC. | $166 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2021 |
| 2021-03-04 | Incyte Corporation | $833 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2021 | |
| 2021-03-03 | Genentech, Inc. | $841 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-03-02 | Cochlear Americas | $194 | Long term medical supply or device loan | In-kind items and services | Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode Device, Implantable hearing solution | 2021 | |
| 2021-03-01 | Merck Sharp & Dohme LLC | $99,457 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2021 |
| 2021-02-28 | Digital Diagnostics Inc. | $90 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-02-26 | Eli Lilly and Company | $5,750 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF LY3127804 IN PATIENTS WHO ARE HOSPITALIZED WITH PNEUMO | 2021 | |
| 2021-02-24 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-02-19 | Incyte Corporation | $8,463 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-02-19 | Incyte Corporation | $6,809 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-02-15 | Boston Scientific Corporation | $76 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US | 2021 |
| 2021-02-10 | Abbott Laboratories | $1,712 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | A safety and effectiveness trial for a leadless pacemaker system | 2021 |
| 2021-02-10 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-02-03 | Tandem Diabetes Care, Inc. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-01-31 | Digital Diagnostics Inc. | $60 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-01-28 | AstraZeneca UK Limited | $33,369 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Le | 2021 |
| 2021-01-27 | Tandem Diabetes Care, Inc. | $1,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-01-26 | Linde Gas & Equipment Inc. | $733 | Space rental or facility fees (teaching hospital only) | In-kind items and services | MM NO800NI-AQ Device, Respiratory | 2021 | |
| 2021-01-22 | Genentech, Inc. | $4,873 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-01-21 | Incyte Corporation | $8,463 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-01-21 | Incyte Corporation | $600 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-01-21 | Incyte Corporation | $64 | Research payment | Cash or cash equivalent | A phase 3 randomized open label multi center study of ruxolitinib vs best available therapy in patients with corticoster | 2021 | |
| 2021-01-20 | Janssen Research & Development, LLC | $7,196 | Research payment | Cash or cash equivalent | A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure | 2021 | |
| 2021-01-20 | Tandem Diabetes Care, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-01-19 | Boston Scientific Corporation | $2,157 | Research payment | Cash or cash equivalent | SQRX Pulse Generator Device, Tachy | STRATEGIC ASSESSMENT OF RANDOMIZED DEFIBRILLATION THERAPY US | 2021 |
| 2021-01-19 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | HEARTLOGIC INTERVENTION PILOT STUDY | 2021 |
| 2021-01-19 | Boston Scientific Corporation | $112 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | HEARTLOGIC INTERVENTION PILOT STUDY | 2021 |
| 2021-01-15 | Digital Diagnostics Inc. | $150 | Research payment | Cash or cash equivalent | IDX-DR Device, Diagnostic Device | IDx-DR | 2021 |
| 2021-01-13 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | IMVIGOR 130 | 2021 |
| 2021-01-12 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2021 |
| 2021-01-12 | Janssen Research & Development, LLC | $655 | Research payment | Cash or cash equivalent | A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure | 2021 | |
| 2021-01-11 | American Regent | $3,355 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2021 |
| 2021-01-07 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2021 | |
| 2021-01-07 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2021 | |
| 2021-01-06 | Endologix LLC | $496 | Research payment | Cash or cash equivalent | AFX2 Bifurcated Endograft System Device, Cardiology/Vascular Diseases | LEOPARD | 2021 |
| 2021-01-05 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Drug | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Fort Wayne, IN, county Allen County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Fort Wayne, IN | County Allen County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 268,589 | 392,378 | 6,851,073 |
| Population, 2020 census P1 | 263,886 | 385,410 | 6,785,528 |
| Median age B01002 | 35.0 | 36.2 | 38.1 |
| Under 18 B01001 | 24.3% | 25.4% | 23.3% |
| 65 and over B01001 | 15.2% | 15.6% | 16.8% |
| Households B11001 | 110,929 | 156,570 | 2,716,009 |
| Foreign born B05002 | 9.0% | 7.8% | 6.3% |
| Median household income B19013 | $61,422 | $70,737 | $71,957 |
| Median family income B19113 | $77,136 | $88,274 | $90,767 |
| Per capita income B19301 | $33,812 | $37,766 | $38,351 |
| Poverty rate B17001 | 16.0% | 12.5% | 12.3% |
| Unemployment rate B23025 | 5.6% | 4.7% | 4.3% |
| Civilian labor force B23025 | 138,501 | 201,715 | 3,472,016 |
| Mean commute (minutes) B08013 | 21.5 | 21.9 | 24.1 |
| Bachelor's degree or higher B15003 | 29.0% | 31.6% | 29.5% |
| Housing units B25001 | 118,657 | 166,285 | 2,976,568 |
| Owner-occupied B25003 | 61.9% | 68.9% | 70.6% |
| Renters B25003 | 38.1% | 31.1% | 29.4% |
| Median home value B25077 | $188,900 | $214,900 | $218,200 |
| Median gross rent B25064 | $999 | $1,021 | $1,062 |
| White, not Hispanic B03002 | 63.2% | 69.8% | 75.4% |
| Black B03002 | 14.0% | 10.5% | 9.1% |
| Hispanic or Latino B03002 | 10.6% | 9.0% | 8.6% |
| Asian B03002 | 6.1% | 5.3% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Fort Wayne, IN.
Comments